Nationwide product launch of NKO® planned for February 2008 in Australia and New Zealand

Neptune Technologies & Bioressources Inc. enters into an exclusive distribution agreement with AZPA International Inc. for Australia and New Zealand

Laval, Québec, CANADA – December 19th, 2007 – Neptune Technologies & Bioressources Inc. (“Neptune”) (NASDAQ.NEPT - TSX.V.NTB) is pleased to announce that it has entered into an exclusive distribution agreement with AZPA International Inc. (“AZPA International”) for Australia and New Zealand. AZPA International, a leading supplier to the pharmaceutical, nutritional health and cosmetics industries, has also acquired non-exclusive rights to commercialize Neptune’s products in Southeast Asia and Hong Kong.

The nationwide product launch of Neptune Krill Oil (NKO®) in Australia and New Zealand, claiming cardiovascular and joint health benefits, is scheduled for February 2008. A pre-requisite for commercializing NKO® in Australia hence New Zealand is obtaining approval as a complementary medicine from the Therapeutic Goods Administration (TGA) which notification Neptune has recently announced.

AZPA International joined forces for the commercialization and distribution of NKO® with PharmaLink Pte. Ltd. (“PharmaLink”), a leading provider of complementary and over-the-counter medicines and a leader in healthcare sales and marketing in the Asia-Pacific region. PharmaLink will be reaching the market through its primary care team, its pharmacy/ OTC team and its specialist/ allied health team.

“It is estimated that 74% of the Australian population has used complementary medicine in the previous twelve months and usage rates are expected to rise,1” said Thierry Houillon, Vice President of Nutraceuticals of Neptune. “An estimated annual increase of 18% has been reported for the complementary medicine market in Australia.2 We are looking forward to working with AZPA International and PharmaLink benefiting from this trend and making NKO® a household name in Australia and New Zealand,” he added.

PharmaLink, in collaboration with AZPA International, will also prepare a comprehensive marketing campaign, including medical conventions, tradeshows, and extensive press and mass media coverage. Selected consumers will be taking NKO® for a period of three months and will subsequently be reporting on radio & TV talk shows about their experience with NKO®.

In addition, AZPA International will be working with Lipa Pharmaceuticals, Australia’s leading contract manufacturer to the nutritional and pharmaceutical industries, which makes products in key growth areas of complementary and alternative medicines, over-the-counter (OTC) and prescription pharmaceuticals.

1. Source: Cardinal Health. Vitamin, Mineral, Herbal and Nutritional Supplements, 4 October 2005
2. Source: Complementary Healthcare Council communication, 13 September 2005.

About Neptune Technologies & Bioressources Inc.
Neptune develops proprietary health ingredients from underexploited marine biomasses, such as krill, with its patented extraction process (Neptune OceanExtract™). Using its proprietary process, the Company is strategically positioning itself in the health and wellness market.

Natural biomass extraction is now playing an important role in developing nutrigenomics, the next wave in nutritional research. Through strategic alliances and partnerships, as well as through clinical studies, the Company continues to demonstrate the beneficial effects of these products. The Company develops and markets new formulas and new products for specific applications in high growth markets such as the nutraceutical, cosmeceutical, biopharmaceutical and nutrigenomics markets.

Neptune continues to strongly support its strategic development plan to form partnerships/strategic alliances with worldwide leaders in the nutraceutical and pharmaceutical industries. Neptune has recently signed agreements with Nestlé and Yoplait, worldwide leading food manufacturers, paving its entrance into the global functional food market. According to its business strategy, negotiations with pharmaceutical companies with the objective of entering the pharmaceutical market by licensing rights are ongoing.